WallStreetZenWallStreetZen

NASDAQ: PMD
Psychemedics Corp Stock

Open Broker Account
$5.36-0.19 (-3.42%)
Updated Dec 9, 2022
PMD Price
$5.36
Fair Value Price
$5.97
Market Cap
$30.23M
52 Week Low
$5.30
52 Week High
$7.85
P/E
-14.88x
P/B
2.58x
P/S
1.4x
PEG
N/A
Dividend Yield
4.86%
Revenue
$25.97M
Earnings
-$2.02M
Gross Margin
35.5%
Operating Margin
-10.53%
Profit Margin
-7.8%
Debt to Equity
0.75
Operating Cash Flow
$4M
Beta
0.5
Next Earnings
N/A
Ex-Dividend
Dec 1, 2022
Next Dividend
Dec 16, 2022

PMD Overview

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Zen Score

Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PMD scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PMD ($5.36) is undervalued by 10.28% relative to our estimate of its Fair Value price of $5.97 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PMD ($5.36) is not significantly undervalued (10.28%) relative to our estimate of its Fair Value price of $5.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more PMD due diligence checks available for Premium users.

Be the first to know about important PMD news, forecast changes, insider trades & much more!

PMD News

Valuation

PMD fair value

Fair Value of PMD stock based on Discounted Cash Flow (DCF)
Price
$5.36
Fair Value
$5.97
Undervalued by
10.20%
PMD ($5.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PMD ($5.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

PMD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-14.88x
Industry
36x
Market
21.21x

PMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.58x
Industry
4.36x
PMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PMD's financial health

Profit margin

Revenue
$6.5M
Net Income
-$97.0k
Profit Margin
-1.5%
PMD's Earnings (EBIT) of -$2.74M... subscribe to Premium to read more.
Interest Coverage Financials
PMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$20.5M
Liabilities
$8.8M
Debt to equity
0.75
PMD's short-term assets ($10.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PMD's short-term assets ($10.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.3M
Investing
-$98.0k
Financing
-$568.0k
PMD's operating cash flow ($3.56M)... subscribe to Premium to read more.
Debt Coverage Financials

PMD vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
PMD$30.23M-3.51%-14.88x2.58x
BWAY$29.90M+1.14%-2.78x0.61x
TRIB$25.88M-3.28%N/A1.64x
SERA$37.53M-3.97%-1.07x0.35x
GENE$21.42M+1.75%-3.43x1.85x

Psychemedics Stock FAQ

What is Psychemedics's quote symbol?

NASDAQ: PMD) Psychemedics trades on the NASDAQ under the ticker symbol PMD. Psychemedics stock quotes can also be displayed as NASDAQ: PMD.

If you're new to stock investing, here's how to buy Psychemedics stock.

What is the 52 week high and low for Psychemedics (NASDAQ: PMD)?

(NASDAQ: PMD) Psychemedics's 52-week high was $7.85, and its 52-week low was $5.30. It is currently -31.78% from its 52-week high and 1.04% from its 52-week low.

How much is Psychemedics stock worth today?

(NASDAQ: PMD) Psychemedics currently has 5,644,696 outstanding shares. With Psychemedics stock trading at $5.36 per share, the total value of Psychemedics stock (market capitalization) is $30.23M.

Psychemedics stock was originally listed at a price of $24.00 in Dec 31, 1997. If you had invested in Psychemedics stock at $24.00, your return over the last 24 years would have been -77.69%, for an annualized return of -6.06% (not including any dividends or dividend reinvestments).

How much is Psychemedics's stock price per share?

(NASDAQ: PMD) Psychemedics stock price per share is $5.36 today (as of Dec 9, 2022).

What is Psychemedics's Market Cap?

(NASDAQ: PMD) Psychemedics's market cap is $30.23M, as of Dec 10, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Psychemedics's market cap is calculated by multiplying PMD's current stock price of $5.36 by PMD's total outstanding shares of 5,644,696.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.